AstraZeneca Admits COVID Vaccine Can Cause ‘Rare Side Effects’

AstraZeneca has admitted for the first time in a recent court document filing that its COVID vaccine can cause “rare side effects.”

The company admitted in court documents, as part of a class action lawsuit filed against them, that its vaccine can cause thrombosis with thrombocytopenia syndrome (TTS).

TTS is reportedly a rare medical condition when a person suffers from blood clots together with a low platelet count.

“Lawyers argue the vaccine produced a side effect which has had a devastating effect on a small number of families,” The Telegraph reported.

“The first case was lodged last year by Jamie Scott, a father of two, who was left with a permanent brain injury after developing a blood clot and a bleed on the brain that has prevented him from working after he received the vaccine in April 2021. The hospital called his wife three times to tell her that her husband was going to die,” the outlet continued.

AstraZeneca is disputing the claims but has accepted that its vaccine “can, in very rare cases, cause TTS”.

In April 2023, American Faith reported that the AstraZeneca COVID shot was “quietly discontinued” from use in the country of Australia after being linked to thrombosis with thrombocytopenia.

The federal health department confirmed that beginning March 2023, the vaccine, sold under the brand-name “Vaxzevria,” would no longer be available to Australians.

Deakin University Chair in Epidemiology, Professor Catherine Bennett said at the time that the removal of the shot was expected after other vaccines emerged, but was kept by the country for people who wanted to “complete their course.”

“It was really only left available for this long for people who had earlier doses of AstraZeneca and wanted to complete their course with it,” Bennett said.